Advancements in nanotherapeutics for Alzheimer’s disease: current perspectives
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Objectives: Considerable progress has been made in the treatment of Alzheimer’s disease (AD), but all available strategies focus on alleviating symptoms rather than curing, which means that AD is viewed as an unresolvable neurodegenerative disease. Nanotechnological applications offer an alternative platform for the treatment of neurodegenerative diseases. This review aims to summarize the recent nanomedicine and nanotechnology developments for the treatment of AD. Key findings: A plethora of nanocarriers and nanoparticle prodrugs have been reported to have negligible cytotoxicity in animal models, and these developments have revealed new opportunities for development of new classes of potent drug formulations for AD. Different nanotechnology-based approaches such as polymers, emulsions, lipo-carriers, solid lipid carriers, carbon nanotubes and metal-based carriers have been developed over the past decade, and they have been focusing on both neuroprotective and neurogenerative techniques to treat AD. Studies also reveal that nanotechnological approaches can aid in early diagnosis of AD and enhance therapeutic efficacy and bioavailability. Summary: Notably, the drugs used conventionally to target the central nervous system have limitations that include an inability to cross the ‘blood–brain barrier’ or the ‘blood–cerebrospinal fluid barrier’ effectively and high drug efflux due to the activity of P-glycoprotein, but these limitations can be successfully overcome when nanocarriers are used for targeted drug delivery in AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Brain Infarction and the Clinical Expression of Alzheimer Disease<subtitle>The Nun Study</subtitle>
Snowdon, D. A. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03540340047031 · Cited by 1,590
Curcumin has potent anti‐amyloidogenic effects for Alzheimer's β‐amyloid fibrils in vitro
Ono, K., Hasegawa, K., Naiki, H., & Yamada, M. (2004) · Journal of Neuroscience Research · doi:10.1002/jnr.20025 · Cited by 1,254
Facts and recommendations about total homocysteine determinations: an expert opinion
Refsum, H., Smith, A. D., Ueland, P. M., Nexo, E., Clarke, R., McPartlin, J., Johnston, C., Engbaek, F., Schneede, J., McPartlin, C., et al. (2004) · Clinical Chemistry · doi:10.1373/clinchem.2003.021634 · Cited by 1,056
Walking and Dementia in Physically Capable Elderly Men
Abbott, R. D. (2004) · JAMA · doi:10.1001/jama.292.12.1447 · Cited by 743
NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo
Eriksen, J. L., Sagi, S. A., Smith, T. E., Weggen, S., Das, P., McLendon, D. C., Ozols, V. V., Jessing, K. W., Zavitz, K. H., Koo, E. H., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18162 · Cited by 634
Using Graphene Oxide High Near‐Infrared Absorbance for Photothermal Treatment of Alzheimer's Disease
Li, M., Yang, X., Ren, J., Qu, K., & Qu, X. (2012) · Advanced Materials · doi:10.1002/adma.201104864 · Cited by 535
Cerebrovascular disease and threshold for dementia in the early stages of Alzheimer's disease
Esiri, M. M., Nagy, Z., Smith, M. Z., Barnetson, L., & Smith, A. D. (1999) · The Lancet · doi:10.1016/s0140-6736(99)02355-7 · Cited by 493
Petrovitch, H., White, L. R., Izmirilian, G., Ross, G. W., Havlik, R. J., Markesbery, W., Nelson, J., Davis, D. G., Hardman, J., Foley, D. J., et al. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00106-8 · Cited by 468 · cited 1×
“Blood pressure may also directly affect the pathology of AD, and mounting evidence indicates hypertension is positively related to higher levels of NFTs and neuritic plaques in the brain.([12,13])”
BackgroundCerebral infarctions and the likelihood of dementia from Alzheimer disease pathology
Schneider, J. A., Wilson, R. S., Bienias, J. L., Evans, D. A., & Bennett, D. A. (2004) · Neurology · doi:10.1212/01.wnl.0000118211.78503.f5 · Cited by 436
Protective Effects of Indian Spice Curcumin Against Amyloid-β in Alzheimer’s Disease
Reddy, P. H., Manczak, M., Yin, X., Grady, M. C., Mitchell, A., Tonk, S., Kuruva, C. S., Bhatti, J. S., Kandimalla, R., Vijayan, M., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170512 · Cited by 354
Cited by
Lamptey, R. N. L., Chaulagain, B., Trivedi, R., Gothwal, A., Layek, B., & Singh, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031851 · Cited by 900
Jeremic, D., Jiménez-Díaz, L., & Navarro-López, J. D. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101496 · Cited by 306
Brown, T. D., Habibi, N., Wu, D., Lahann, J., & Mitragotri, S. (2020) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.0c00743 · Cited by 182
p53: from understanding its structure to advances in therapeutic targeting
Wang, W., Liu, X., Liu, H., Abolhassani, H., Yan, H., Zhang, H., & Wang, X. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02549-5 · Cited by 30
Metadata
- Authors
- Harilal, S., Jose, J., Parambi, D. G. T., Kumar, R., Mathew, G. E., Uddin, M. S., Kim, H., & Mathew, B.
- Venue
- Journal of Pharmacy and Pharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-09-01
- Volume
- 71
- Issue
- 9
- Pages
- 1370-1383
- ISSN
- 0022-3573 (ISSN-L)
- 2042-7158
- OpenAlex
- W2962613241
- Cited by
- 154
- References
- 16
- FWCI
- 12.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Advancements in nanotherapeutics for Alzheimer’s disease: current perspectives. https://app.cochat.ai/papers/10.1111/jphp.13132
- The paper
- Harilal, S., Jose, J., Parambi, D. G. T., Kumar, R., Mathew, G. E., Uddin, M. S., Kim, H., & Mathew, B. (2019). Advancements in nanotherapeutics for Alzheimer’s disease: current perspectives. Journal of Pharmacy and Pharmacology. https://doi.org/10.1111/jphp.13132
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.